BE Pharmaceuticals Inc.
13 drugs in NADAC|13 Generic,0 Brand
BE Pharmaceuticals Inc. lists 13 NDCs in the CMS NADAC file (13 generic, 0 brand), at an average NADAC of $10.53 per unit, with a week-over-week move of -2.2% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
13
13G / 0B
Avg Price / Unit
$10.5250
$0.39 – $38.51
Avg 7d Change
-2.17%
Across 9 drugs with changes
7d Activity
of 13 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
enoxaparin sodium market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Low Molecular Weight Heparin therapeutic class
Review the broader class where BE Pharmaceuticals Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does BE Pharmaceuticals Inc. make?
BE Pharmaceuticals Inc. lists 13 NDCs in the CMS NADAC file — 13 generic and 0 brand products.
What is the average price of BE Pharmaceuticals Inc. drugs?
The average NADAC across BE Pharmaceuticals Inc.'s portfolio is $10.5250 per unit, ranging from $0.3942 to $38.5080.
What types of drugs does BE Pharmaceuticals Inc. make?
BE Pharmaceuticals Inc. makes drugs across 6 FDA pharmacologic classes. The most common by NDC count are Low Molecular Weight Heparin (7), Lipopeptide Antibacterial (2), Substance P/Neurokinin-1 Receptor Antagonist (1), Proton Pump Inhibitor (1), Anticholinergic (1).
Has BE Pharmaceuticals Inc. had any drug recalls?
No FDA enforcement recalls are matched to BE Pharmaceuticals Inc. in the openFDA feed.
How has BE Pharmaceuticals Inc.'s pricing changed recently?
Over the past 7 days, 2 BE Pharmaceuticals Inc. products rose and 7 fell, with a portfolio-wide average change of -2.2%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
FOSAPREPITANT 150 MG VIAL fosaprepitant | $38.5080 per EA | — |
DAPTOMYCIN 500 MG VIAL daptomycin | $23.7984 per EA | +4.90% |
DAPTOMYCIN 350 MG VIAL daptomycin | $13.4180 per EA | — |
ENOXAPARIN 120 MG/0.8 ML SYR enoxaparin sodium | $10.4173 per ML | -4.36% |
ENOXAPARIN 30 MG/0.3 ML SYR enoxaparin sodium | $9.1268 per ML | -4.83% |
ENOXAPARIN 150 MG/ML SYRINGE enoxaparin sodium | $8.9038 per ML | -7.60% |
ENOXAPARIN 40 MG/0.4 ML SYR enoxaparin sodium | $7.7791 per ML | -4.26% |
ENOXAPARIN 60 MG/0.6 ML SYR enoxaparin sodium | $7.4522 per ML | -2.23% |
ENOXAPARIN 80 MG/0.8 ML SYR enoxaparin sodium | $6.6868 per ML | -1.27% |
ENOXAPARIN 100 MG/ML SYRINGE enoxaparin sodium | $6.4517 per ML | -2.15% |
PANTOPRAZOLE SODIUM 40 MG VIAL Pantoprazole sodium | $2.3740 per EA | — |
GLYCOPYRROLATE 0.2 MG/ML VIAL glycopyrrolate | $1.5143 per ML | +2.28% |
ROCURONIUM 50 MG/5 ML VIAL rocuronium bromide | $0.3942 per ML | — |